4 January 2018
Belleville, Ontario - NovaVive Inc., an animal health immunobiology company, today announced that Robert (Bob) Barclay has joined the NovaVive team as Senior Vice-President, U.S. Sales & Marketing effective January 1, 2018.
Bob comes to NovaVive with several years of experience in animal health, including 11 years with Zoetis Inc. (formerly Pfizer Animal Health) as Associate Director of Business Development. Beyond his business development expertise, which involved leading and supporting various transactions (in-licensing deals, distribution deals, corporate acquisitions, etc.), Bob also managed Rimadyl, Pfizer’s flagship companion animal pain management product.
Bob has an MBA with a concentration in Finance and Marketing from the John M. Olin School of Business, Washington University, as well as MS and BS degrees in Animal Science from the University of Illinois.
“We are pleased to welcome Bob to the NovaVive team,” said Graeme McRae, President of NovaVive Inc. “His marketing and business development expertise will help us to identify, assess and execute new business opportunities, partnerships and growth strategies. He will play an active role in growing our U.S. business by promoting our five USDA-approved immunotherapeutics through our veterinary distributors.”
Bob will be based in Norwalk, CT and can be reached by email - Robert.Barclay@NovaVive.ca or phone - 917-817-0657.
About NovaVive Inc.
NovaVive is a private company founded in July, 2014. The Company has an advanced veterinary immunotherapeutic platform based on mycobacterium cell wall fraction (MCWF) technology with 5 regulator-approved products in the U.S. Certain formulations have demonstrated the capability of reducing the reliance on antibiotics in the treatment of bacterial diseases of horses and cattle or effectively treating viral equine respiratory disease. Other formulations have been developed as anticancer therapies in dogs and horses. The Company’s development plan is to identify additional livestock and companion animal diseases that may be effectively treated with its immunotherapeutic technology platform. For more information about the Company, please visit www.NovaVive.ca, or contact: